WorldCat Linked Data Explorer

Turtle N-Triple JSON-LD RDF/XML HTML Contact Us Home

http://worldcat.org/entity/work/id/1011502655

Target Validation in Drug Discovery

This work presents a comprehensive contemporary framework for approaching target validation in drug discovery. It begins with a detailed description of new enabling technologies, including aptamers, RNA interference, functional genomics, and proteomics. The next section looks at biologic drug development with in-depth discussion of lessons learned from such well-known cases as Erbitux, Herceptin, and Avastin. Additional targets known as "second generation" drugs, which can be identified when disease pathways are validated by biologics, present new possible small molecule therapeutics and serve as the focus of the final section of the book.

Open All Close All

type

about

http://schema.org/about

alternateName

http://schema.org/alternateName

  • "Pharmaceutical Biotechnology for Target Validation"
  • "Target Validation for Biopharmaceutical Drug Discovery"
  • "Validating Targets of Small Molecule Approaches"

contributor

creator

description

http://schema.org/description

  • "This work presents a comprehensive contemporary framework for approaching target validation in drug discovery. It begins with a detailed description of new enabling technologies, including aptamers, RNA interference, functional genomics, and proteomics. The next section looks at biologic drug development with in-depth discussion of lessons learned from such well-known cases as Erbitux, Herceptin, and Avastin. Additional targets known as "second generation" drugs, which can be identified when disease pathways are validated by biologics, present new possible small molecule therapeutics and serve as the focus of the final section of the book."@en
  • "This work presents a comprehensive contemporary framework for approaching target validation in drug discovery. It begins with a detailed description of new enabling technologies, including aptamers, RNA interference, functional genomics, and proteomics. The next section looks at biologic drug development with in-depth discussion of lessons learned from such well-known cases as Erbitux, Herceptin, and Avastin. Additional targets known as "second generation" drugs, which can be identified when disease pathways are validated by biologics, present new possible small molecule therapeutics and serve as the focus of the final section of the book."
  • "This work presents a comprehensive contemporary framework for approaching target validation in drug discovery. It begins with a detailed description of new enabling technologies, including aptamers, RNA interference, functional genomics, and proteomics."@en

editor

genre

http://schema.org/genre

  • "Ressource Internet (Descripteur de forme)"
  • "Livre électronique (Descripteur de forme)"
  • "Electronic books"
  • "Electronic books"@en
  • "Livres électroniques"
  • "Llibres electrònics"

name

http://schema.org/name

  • "<&gt"
  • "Target Validation in Drug Discovery"@en
  • "Target Validation in Drug Discovery"
  • "Target validation in drug discovery"
  • "Target validation in drug discovery"@en
  • "Target validation in drug discovery = 药物发现中的靶标确认"

workExample